Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth.

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (HIMS +5.89%), an estimated $18.07 million trade based on quarterly

BofA Securities analyst Allen Lutz upgraded Hims and Hers from Underperform to Neutral with a price target of $23.00, up from $12.50. The analyst raised the price objective to reflect a 23x CY26E EV/EBITDA multiple, which now includes GLP-1 revenue.

Hims & Hers is downgraded to hold as the 40% rally after Novo Nordisk’s dismissal of its lawsuit is likely driven by a short squeeze. Read my HIMS stock update.

Wondering whether Hims & Hers Health is starting to look attractively priced, or if the market is still getting ahead of itself? This article walks through what the numbers are really saying about its value.

Wall Street's major averages ended lower on Friday after nonfarm payrolls unexpectedly contracted in February and oil prices continued to rise. The benchmark S&P 500 closed -1.3%, while the Nasdaq Composite finished -1.